RBC Capital Mkts Just Issued “Outperform” Rating on SCYNEXIS Inc (SCYX)

SCYNEXIS Inc (SCYX) was Reiterated by RBC Capital Mkts to “Outperform” while Lowering the Price Target of the company shares to $ 11 from a previous price target of $15 . RBC Capital Mkts advised their Clients and Investors in a research report released on Mar 3, 2017.

Based on several research reports , Shares were Reiterated by RBC Capital Mkts on Mar 3, 2017 to “Outperform” and Lowered the Price Target to $ 11 from a previous price target of $15 .Shares were Reiterated by RBC Capital Mkts on Mar 3, 2017 to “Outperform” and Lowered the Price Target to $ 11 from a previous price target of $15 .

Several company insiders have filed Insider transactions , on Dec 22, 2016, Marco Taglietti (CEO) purchased 25,000 shares at $3.30 per share price. According to the SEC, on Dec 19, 2016, Gonzalez David Angulo (Chief Medical Officer) purchased 4,000 shares at $3.25 per share price. On Sep 16, 2016, Patrick Machado (director) purchased 40,000 shares at $2.94 per share price, according to the Form-4 filing with the securities and exchange commission.

SCYNEXIS Inc opened for trading at $3.42 and hit $3.4699 on the upside on Monday, eventually ending the session at $3.43, with a gain of 0.88% or 0.03 points. The heightened volatility saw the trading volume jump to 1,91,344 shares. Company has a market cap of $82 M.

SCYNEXIS Inc. is a pharmaceutical company. The Company is engaged in the discovery development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate SCY-078 is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species including drug resistant strains. In addition the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635 which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641 which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.

SCYNEXIS Inc

You might also like

Leave a Reply

Your email address will not be published. Required fields are marked *